Cost-effectiveness analysis of bevacizumab combined with chemotherapy for the treatment of metastatic colorectal cancer in Japan.

Abstract

BACKGROUND Rapid progress has been made in the treatment of metastatic colorectal cancer (mCRC). New treatment regimens for mCRC include not only cytotoxic chemotherapy but also targeted monoclonal antibodies, including bevacizumab. However, bevacizumab is an expensive medication, which costs from 300,000 yen to 400,000 yen (US $2500-$3300) per month… (More)

Topics

Cite this paper

@article{Shiroiwa2007CosteffectivenessAO, title={Cost-effectiveness analysis of bevacizumab combined with chemotherapy for the treatment of metastatic colorectal cancer in Japan.}, author={Takeru Shiroiwa and Takashi Fukuda and Kiichiro Tsutani}, journal={Clinical therapeutics}, year={2007}, volume={29 10}, pages={2256-67} }